Los verdaderos alcances de la renegociación de la deuda externa de México

El acuerdo de renegociación de la deuda externa firmado el domingo 23 de julio de 1989, a pesar de su alcance innegable, histórico, no puede dejar de considerarse como limitado y modesto respecto a lo que se había esperado semans y meses antes de la fecha del acuerdo. Este artículo trata de demostrar que esa paradójica situación tiene alcances limitados en lo acordado, por un lado, y explosivas manifestaciones de jubilo por lo logrado, por el otro. 1) Qué fue lo que se consiguió o es previsible que se consiga, directamente del acuerdo, es decir de parte de los acreedores bancarios y, 2) Cuáles son los efectos que indirecta o internamente se buscarán alcanzar a raíz del convenio

Momento Económico (46)

En este número Momento político: La ofensiva conservadora y la nueva Ley Federal del trabajo, Víctor M. Bemal Sahagún 2. ¿De cuál desarrollo y de cuáles regiones se trata en el Plan Nacional?, Angel Bassols Batalla 3. El Plan Nacional de Desarrollo 1989-1 994, Luis Fuentes Aguilar 10. Fernando Carmona de la Peña: Maestro emérito, Benito Rey Romay 12. José Luis Ceceiía Camez, Maestro emérito, Alma Chapoy Bonifaz y Salvador Martínez Della Roca 13. La deuda externa del llamado Tercer Mundo y la paz, Ramón Matínez Escamilla 14. Cananea: entre la quiebra y la privatización otro golpe a los trabajadores, José Casca Zamora 17. Paraestatales: Telmex y Pemex, Arturo Bonilla y Sergio Suárez Guevara 20. Los verdaderos alcances de la renegociación de la deuda externa de México, José Lorenzo Santos Valle 22. Indicadores económicos: México balance económico de los sectores primer semestre de 1989, Clara Eugenia Aranda 25. Temas de hoy José Antonio Moreno 32

Impact of operatoŕs experience on peri-procedural outcomes with Watchman FLX: Insights from the FLX-SPA registry

Background: The Watchman FLX is a device upgrade of the Watchman 2.5 that incorporates several design enhancements intended to simplify left atrial appendage occlusion (LAAO) and improve procedural outcomes. This study compares peri-procedural results of LAAO with Watchman FLX (Boston Scientific, Marlborough, Massachusetts) in centers with varying degrees of experience with the Watchman 2.5 and Watchman FLX. Methods: Prospective, multicenter, 'real-world' registry including consecutive patients undergoing LAAO with the Watchman FLX at 26 Spanish sites (FLX-SPA registry). Implanting centers were classified according to the center's prior experience with the Watchman 2.5. A further division of centers according to whether or not they had performed ≤ 10 or > 10Watchman FLX implants was prespecified at the beginning of the study. Procedural outcomes of institutions stratified according to their experience with the Watchman 2.5 and FLX devices were compared. Results: 359 patients [mean age 75.5 (SD8.1), CHA2DS2-VASc 4.4 (SD1.4), HAS-BLED 3.8(SD0.9)] were included. Global success rate was 98.6%, successful LAAO with the first selected device size was achieved in 95.5% patients and the device was implanted at first attempt in 78.6% cases. There were only 9(2.5%) major peri-procedural complications. No differences in efficacy or safety results according to the centeŕs previous experience with Watchman 2.5 and procedural volume with Watchman FLX existed. Conclusions: The Watchman FLX attains high procedural success rates with complete LAA sealing in unselected, real-world patients, along with a low incidence of peri-procedural complications, regardless of operatoŕs experience with its previous device iteration or the number of Watchman FLX devices implanted

Administración financiera del estado cubano

El presente libro sobre “La Administración Financiera del Estado Cubano”, que se realizó en el marco del programa de “Formación en Economía para Altos Funcionarios del Gobierno de Cuba” y que se inscribe en el acuerdo de Cooperación Técnica entre los gobiernos de Cuba y Uruguay, financiado por la Agencia Sueca de Cooperación Internacional (Asdi), es el producto del trabajo de un grupo de profesionales cubanos que han encabezado el proceso de modernización de las finanzas públicas en Cuba, y la participación de un destacado economista uruguayo. Este texto es evaluado por el Ministerio de Finanzas y Precios de la República de Cuba como una necesidad para la formación y actualización de los especialistas que lo integran, y recoge, a su vez, los aportes de otros proyectos de investigación y cursos específicos también desarrollados en el programa de referencia, que no se cubren de forma integral en los actuales programas que se dictan tanto a nivel de pregrado como de postgrado. Con este libro, por primera vez se logra un material que muestra la implementación de los sistemas de la administración financiera del Estado o su perfeccionamiento en Cuba, adecuando instrumentos y experiencias internacionales a las condiciones de la economía cubana.Presentación -- Prólogo -- 1. ÁMBITO DE LAS FINANZAS PÚBLICAS / Isaac Umansky, Arely Benítez Fernández, Noel Chaviano Saldaña -- 2. LA ADMINISTRACIÓN FINANCIERA DEL ESTADO Y LOS SISTEMAS FINANCIEROS / José Carlos del Toro Ríos -- 3. SISTEMA PRESUPUESTARIO / Carlos Manuel Santos Cid, Miriam Peralta del Valle, C. Manuel López García -- 4. SISTEMA TRIBUTARIO / Luis Francisco Suero, Antonio Fonteboa Vizcaíno -- 5. SISTEMA DE TESORERÍA / Carlos Manuel Santos Cid, Odalis Gastardi Picó, Adalberto Carbonell Sotto, Luciano Otero Riera -- 6. SISTEMA DEL CRÉDITO PÚBLICO / Arely Benítez Fernández, José Eloy Llaguno Barres -- 7. SISTEMA DE CONTABILIDAD GUBERNAMENTAL / Selma Peison Lorenzo, Caridad Reyes Hernández, Carlos Manuel Santos Cid, Raquel Hernández Herrera -- BIBLIOGRAFÍA -- ANEXO

Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

Background Atrial fibrillation (AF) may exist before or occur early in the course of pulmonary embolism (PE). We determined the PE outcomes based on the presence and timing of AF. Methods and Results Using the data from a multicenter PE registry, we identified 3 groups: (1) those with preexisting AF, (2) patients with new AF within 2 days from acute PE (incident AF), and (3) patients without AF. We assessed the 90-day and 1-year risk of mortality and stroke in patients with AF, compared with those without AF (reference group). Among 16 497 patients with PE, 792 had preexisting AF. These patients had increased odds of 90-day all-cause (odds ratio [OR], 2.81; 95% CI, 2.33-3.38) and PE-related mortality (OR, 2.38; 95% CI, 1.37-4.14) and increased 1-year hazard for ischemic stroke (hazard ratio, 5.48; 95% CI, 3.10-9.69) compared with those without AF. After multivariable adjustment, preexisting AF was associated with significantly increased odds of all-cause mortality (OR, 1.91; 95% CI, 1.57-2.32) but not PE-related mortality (OR, 1.50; 95% CI, 0.85-2.66). Among 16 497 patients with PE, 445 developed new incident AF within 2 days of acute PE. Incident AF was associated with increased odds of 90-day all-cause (OR, 2.28; 95% CI, 1.75-2.97) and PE-related (OR, 3.64; 95% CI, 2.01-6.59) mortality but not stroke. Findings were similar in multivariable analyses. Conclusions In patients with acute symptomatic PE, both preexisting AF and incident AF predict adverse clinical outcomes. The type of adverse outcomes may differ depending on the timing of AF onset.info:eu-repo/semantics/publishedVersio

Healthcare workers hospitalized due to COVID-19 have no higher risk of death than general population. Data from the Spanish SEMI-COVID-19 Registry

Aim To determine whether healthcare workers (HCW) hospitalized in Spain due to COVID-19 have a worse prognosis than non-healthcare workers (NHCW). Methods Observational cohort study based on the SEMI-COVID-19 Registry, a nationwide registry that collects sociodemographic, clinical, laboratory, and treatment data on patients hospitalised with COVID-19 in Spain. Patients aged 20-65 years were selected. A multivariate logistic regression model was performed to identify factors associated with mortality. Results As of 22 May 2020, 4393 patients were included, of whom 419 (9.5%) were HCW. Median (interquartile range) age of HCW was 52 (15) years and 62.4% were women. Prevalence of comorbidities and severe radiological findings upon admission were less frequent in HCW. There were no difference in need of respiratory support and admission to intensive care unit, but occurrence of sepsis and in-hospital mortality was lower in HCW (1.7% vs. 3.9%; p = 0.024 and 0.7% vs. 4.8%; p<0.001 respectively). Age, male sex and comorbidity, were independently associated with higher in-hospital mortality and healthcare working with lower mortality (OR 0.211, 95%CI 0.067-0.667, p = 0.008). 30-days survival was higher in HCW (0.968 vs. 0.851 p<0.001). Conclusions Hospitalized COVID-19 HCW had fewer comorbidities and a better prognosis than NHCW. Our results suggest that professional exposure to COVID-19 in HCW does not carry more clinical severity nor mortality

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Search for heavy resonances decaying to two Higgs bosons in final states containing four b quarks

A search is presented for narrow heavy resonances X decaying into pairs of Higgs bosons (H) in proton-proton collisions collected by the CMS experiment at the LHC at root s = 8 TeV. The data correspond to an integrated luminosity of 19.7 fb(-1). The search considers HH resonances with masses between 1 and 3 TeV, having final states of two b quark pairs. Each Higgs boson is produced with large momentum, and the hadronization products of the pair of b quarks can usually be reconstructed as single large jets. The background from multijet and t (t) over bar events is significantly reduced by applying requirements related to the flavor of the jet, its mass, and its substructure. The signal would be identified as a peak on top of the dijet invariant mass spectrum of the remaining background events. No evidence is observed for such a signal. Upper limits obtained at 95 confidence level for the product of the production cross section and branching fraction sigma(gg -> X) B(X -> HH -> b (b) over barb (b) over bar) range from 10 to 1.5 fb for the mass of X from 1.15 to 2.0 TeV, significantly extending previous searches. For a warped extra dimension theory with amass scale Lambda(R) = 1 TeV, the data exclude radion scalar masses between 1.15 and 1.55 TeV

Measurement of the top quark mass using charged particles in pp collisions at root s=8 TeV

Peer reviewe